Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Mills, Inc. (GIS) vs Medpace Holdings Inc (MEDP) Price & Performance

General Mills, Inc.Trade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

General Mills, Inc. vs Medpace Holdings Inc — how do they compare? General Mills, Inc. trades at $37.93 (market cap $20.24B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.43% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

GISMEDP
Market Cap
$20.24B$16.90B
Sector
Consumer StaplesTechnology
52-Week High
$51.11$620.59
52-Week Low
$32.17$393.42
Enterprise Value
$33.73B$16.52B
Dividend Yield
6.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Mills, Inc.

General Mills (GIS) trades at $38.21, up 2.55% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings show volatility, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue has declined from $20.1B in 2023 to $19.5B in 2025, with net income margin turning negative at -0.48% for 2026. The company maintains a dividend and is pursuing cost savings initiatives, while debt-to-asset ratio has risen to 45% in 2025.

Outlook is cautious; the stock offers a low P/E of 9.23 and dividend income, but faces headwinds from weak sales, margin pressure, and high debt. Analyst consensus is mixed with 22% buy, 61% hold ratings. Key risks include competitive pressures and execution of turnaround plans. Investors should weigh valuation appeal against fundamental challenges.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About General Mills, Inc.

General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.

Read more on GIS

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP